Devicor Medical Products acquires entire EES Breast Care product portfolio

Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today announced it has completed the divestiture of its Breast Care business to Devicor Medical Products, Inc., a portfolio company of GTCR. Financial terms of the transaction are not being disclosed.

Under the terms of the transaction, Devicor has acquired the entire EES Breast Care product portfolio, including the MAMMOTOME® Breast Biopsy System and tissue markers (MammoMARK®, MicroMARK®, and CoreMARK®) used for breast disease diagnostic sampling and management.  Additionally, EES has transferred marketing and distribution rights for Neoprobe® Gamma Detection Systems to Devicor.  Approximately 300 employees supporting the business will transfer to Devicor, subject to local laws.

"Associates in the Breast Care business have made it what it is today: the global leader in vacuum assisted breast biopsy devices," said Karen Licitra, Company Group Chairman, and Worldwide Franchise Chairman, Ethicon Endo-Surgery.  "The MAMMOTOME® brand is recognized worldwide, and we believe Devicor provides a promising fit to help the Breast Care business achieve its full potential."

Source:

Ethicon Endo-Surgery, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Low-carb diet may improve beta-cell function in type 2 diabetes patients